Photodynamic therapy of early squamous cell carcinoma with tetra(m-hydroxyphenyl)chlorin: optimal drug-light interval
1997

Photodynamic Therapy for Early Squamous Cell Carcinoma

Sample size: 5 publication Evidence: moderate

Author Information

Author(s): S Andrejevic-Blant, Ch Hadjur, J-P BalIini, G Wagnieres, Ch Fontolliet, H van den Bergh, Ph Monnier

Primary Institution: Department of Otolaryngology, Head and Neck Surgery-CHUV Hospital, Lausanne, Switzerland

Hypothesis

What is the optimal drug-light interval for effective photodynamic therapy of early squamous cell carcinomas?

Conclusion

The study suggests that a drug-light interval of 4 to 8 days after injection of mTHPC is optimal for photodynamic therapy of early malignancies.

Supporting Evidence

  • Photodynamic therapy showed greater damage to early squamous cell carcinomas compared to healthy mucosae at drug-light intervals between 3 and 8 days.
  • Significant differences in tissue damage were observed at various drug-light intervals.
  • Fluorescence microscopy indicated that the biodistribution of mTHPC changes over time.

Takeaway

This study found that waiting 4 to 8 days after giving a special medicine before shining a light on cancer can help treat it better.

Methodology

The study used a Syrian hamster cheek pouch tumor model to evaluate the effects of different drug-light intervals on photodynamic therapy.

Limitations

The study was conducted in an animal model, which may not fully replicate human responses.

Participant Demographics

Syrian hamsters were used as the animal model.

Statistical Information

P-Value

p<0.05

Statistical Significance

p<0.05

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication